<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26563449</PMID><DateCompleted><Year>2016</Year><Month>12</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of molecular neuroscience : MN</Title><ISOAbbreviation>J Mol Neurosci</ISOAbbreviation></Journal><ArticleTitle>Inhibition of the Androgen Receptor by Antiandrogens in Spinobulbar Muscle Atrophy.</ArticleTitle><Pagination><StartPage>343</StartPage><EndPage>347</EndPage><MedlinePgn>343-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12031-015-0681-8</ELocationID><Abstract><AbstractText>Spinal-bulbar muscle atrophy (SBMA) or also named Kennedy's Disease is caused by a polyglutamine expansion (PolyQ) of the coding region of the androgen receptor (AR). The AR is a ligand-controlled transcription factor and member of the nuclear hormone receptor superfamily. The central characteristics of the SBMA pathogenicity are muscle weakness, the loss of motoneurons and the occurrence of AR-containing protein aggregates that are observed in spinal cord motoneurons and skeletal muscles induced by the AR-PolyQ expansion in the presence of androgens. The PolyQ triggers a misfolding in the AR-PolyQ and leads to protein aggregation in spinal cord motoneurons and muscle cells. The AR-PolyQ toxicity is activated by the AR ligand testosterone and dihydrotestosterone that activate the receptor and triggers nuclear toxicity by inducing AR nuclear translocation. In line with this, androgen treatment of SBMA patients worsened the SBMA symptoms. SBMA has been modeled in AR-overexpressing and AR-PolyQ-knock-in animals, but precisely how the PolyQ expansion leads to neurodegeneration is unclear. The androgen-induced toxicity and androgen-dependent nuclear accumulation of AR-PolyQ protein seems to be central to the pathogenesis. Therefore, the inhibition of the androgen-activated AR-PolyQ might be a therapeutic option. Here the use of AR antagonists for treatment option of SBMA will be reviewed and discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baniahmad</LastName><ForeName>Aria</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Human Genetics, Jena University Hospital, 07740, Jena, Germany. aria.baniahmad@med.uni-jena.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mol Neurosci</MedlineTA><NlmUniqueID>9002991</NlmUniqueID><ISSNLinking>0895-8696</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059002">Androgen Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D059002" MajorTopicYN="N">Androgen Receptor Antagonists</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019680" MajorTopicYN="N">Trinucleotide Repeat Expansion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kennedy&#x2019;s Disease</Keyword><Keyword MajorTopicYN="N">Neurotoxicity</Keyword><Keyword MajorTopicYN="N">Polyglutamine expansion syndrome</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26563449</ArticleId><ArticleId IdType="doi">10.1007/s12031-015-0681-8</ArticleId><ArticleId IdType="pii">10.1007/s12031-015-0681-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neural Plast. 2012;2012:369284</Citation><ArticleIdList><ArticleId IdType="pubmed">22720173</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Exp Med Biol. 2010;685:64-74</Citation><ArticleIdList><ArticleId IdType="pubmed">20687495</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Neurol. 2011 Feb;10(2):140-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neuroendocrinol. 2011 Oct;32(4):416-25</Citation><ArticleIdList><ArticleId IdType="pubmed">21745497</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 1999 May;8(5):731-41</Citation><ArticleIdList><ArticleId IdType="pubmed">10196362</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 2006 Oct;116(10 ):2663-72</Citation><ArticleIdList><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Neurosci. 2013 Jul;50(3):514-23</Citation><ArticleIdList><ArticleId IdType="pubmed">23420040</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 2003 Dec 31;213(1):79-85</Citation><ArticleIdList><ArticleId IdType="pubmed">15062576</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocrinology. 2014 Jul;155(7):2624-34</Citation><ArticleIdList><ArticleId IdType="pubmed">24742193</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 May 8;324(5928):787-90</Citation><ArticleIdList><ArticleId IdType="pubmed">19359544</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2002 Nov 15;13(16):2117-20</Citation><ArticleIdList><ArticleId IdType="pubmed">12438937</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2007 Sep 1;67(17):8388-95</Citation><ArticleIdList><ArticleId IdType="pubmed">17804755</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuron. 2010 Sep 23;67(6):936-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2010 Nov 12;285(46):35567-77</Citation><ArticleIdList><ArticleId IdType="pubmed">20826791</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Tissue Res. 2012 Jul;349(1):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">22476656</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Endocrinol. 2014 Nov;28(11):1831-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25203674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem. 2010 Oct 1;18(19):6960-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20826091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2000 Jan 1;9(1):133-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10587588</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharmacol Sin. 2015 Jan;36(1):3-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24909511</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2008 Jan;79(1):106-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17056629</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochim Biophys Acta. 2012 Jun;1822(6):1070-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22366762</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurodegener Dis. 2011;8(1-2):25-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20689246</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurobiol Aging. 2013 Nov;34(11):2585-603</Citation><ArticleIdList><ArticleId IdType="pubmed">23810450</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1206-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15258239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Endocrinol. 2006 May;20(5):1048-60</Citation><ArticleIdList><ArticleId IdType="pubmed">16373395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Cell Endocrinol. 2011 Jan 30;332(1-2):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20965230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2015 Jan 1;24(1):64-75</Citation><ArticleIdList><ArticleId IdType="pubmed">25122660</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Biol. 2000 Apr 17;149(2):255-62</Citation><ArticleIdList><ArticleId IdType="pubmed">10769019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Endocrinol. 2002 Apr;16(4):661-73</Citation><ArticleIdList><ArticleId IdType="pubmed">11923464</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncotarget. 2015 Nov 3;6(34):35542-55</Citation><ArticleIdList><ArticleId IdType="pubmed">26325261</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cell Mol Med. 2009 Aug;13(8B):2210-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18627423</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2012 Dec;99(3):246-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22609045</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mol Genet. 2009 Jun 1;18(11):1937-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19279159</ArticleId></ArticleIdList></Reference><Reference><Citation>Endocr Relat Cancer. 2014 Aug;21(4):T105-18</Citation><ArticleIdList><ArticleId IdType="pubmed">24639562</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>